Burke, J. M., Bartlett, N., Simmons, G. L., Fitzgerald, L., Abramson, J., Merchant, A., Caimi, P., Patel, R. D., Stevens, D., Vos, S. D., Krijanovski, O. L., Shouse, G., Herrera, A., Holmes, H., Matasar, M., Gandhi, M., Locke, F., Kuruvilla, J., Feng, A., Jiang, J., Shahani, S., Gall, J. B. L., Roberts, Z. J., Westin, J. (2025). First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study. Blood. https://doi.org/10.1182/blood-2025-3730